Source comparison
CJC-1295 SubQ vs IM Injection Route: Full Comparison
Before selecting an administration route, understand what each variable actually affects. And what it doesn't. Bioavailability 94–97% (abdominal tissue, properly reconstituted) 92–96% (vastus lateralis, ventrogluteal sites) Statistically equivalent. Route does
This comparison does not assign a generated winner or score.
- Before selecting an administration route, understand what each variable actually affects. And what it doesn't.
- Bioavailability
- 94–97% (abdominal tissue, properly reconstituted)
- 92–96% (vastus lateralis, ventrogluteal sites)
- Statistically equivalent. Route does not meaningfully affect systemic absorption
- Time to Peak Plasma Concentration (Tmax)
- 60–90 minutes
- 60–120 minutes
- No clinically significant difference for a peptide with 6–8 day half-life
- Needle Gauge / Length
- 25–27G, 4–6mm penetration depth
- 21–23G, 25–38mm penetration depth
- SubQ uses smaller needles, reducing procedural pain and tissue disruption
- Post-Injection Site Pain >24hrs
- 3–5% incidence in controlled studies
- 12–18% incidence in controlled studies
- SubQ significantly reduces persistent injection site discomfort
- Hematoma Formation Risk
- 2–4%
- 8–11%
- IM carries 2–3× higher bruising risk due to deeper vascular penetration
- Vascular/Nerve Injury Risk
- Minimal (no major structures within 4–6mm depth)
- Moderate (femoral artery, sciatic nerve proximity at common IM sites)
- SubQ avoids anatomical hazard zones entirely